GLAND - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.9
| Stock Code | GLAND | Market Cap | 29,182 Cr. | Current Price | 1,773 ₹ | High / Low | 2,131 ₹ |
| Stock P/E | 24.6 | Book Value | 610 ₹ | Dividend Yield | 1.02 % | ROCE | 15.8 % |
| ROE | 11.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,745 ₹ | DMA 200 | 1,767 ₹ |
| Chg in FII Hold | -0.29 % | Chg in DII Hold | 0.37 % | PAT Qtr | 326 Cr. | PAT Prev Qtr | 302 Cr. |
| RSI | 53.1 | MACD | 15.2 | Volume | 1,98,621 | Avg Vol 1Wk | 1,43,720 |
| Low price | 1,383 ₹ | High price | 2,131 ₹ | PEG Ratio | -7.17 | Debt to equity | 0.00 |
| 52w Index | 52.2 % | Qtr Profit Var | 10.4 % | EPS | 71.0 ₹ | Industry PE | 30.9 |
📊 Gland Pharma shows moderate fundamentals with ROCE at 15.8% and ROE at 11.6%, which are decent but not exceptional. The company is debt-free, ensuring financial stability. Dividend yield of 1.02% provides modest income. The P/E of 24.6 is below the industry average of 30.9, suggesting fair valuation. However, the negative PEG ratio (-7.17) indicates weak growth prospects relative to valuation. Current price ₹1,773 is near both 50 DMA (₹1,745) and 200 DMA (₹1,767), showing consolidation. Quarterly PAT growth is modest (10.4%).
💡 Ideal Entry Zone: ₹1,650 – ₹1,720 (near support levels).
📈 Exit Strategy: Investors already holding may consider a medium-term horizon (2–3 years) unless growth metrics improve. Partial profit booking can be done near ₹2,050–₹2,100 resistance levels. Long-term holding should be cautious given weak PEG ratio and moderate profitability.
Positive
- Debt-free balance sheet ensures financial stability.
- P/E of 24.6 is lower than industry average (30.9).
- Quarterly PAT growth of 10.4% shows steady improvement.
- DII holdings increased (+0.37%), reflecting domestic institutional confidence.
Limitation
- ROE (11.6%) and ROCE (15.8%) are moderate compared to peers.
- Negative PEG ratio (-7.17) signals weak growth prospects.
- FII holdings decreased (-0.29%), showing reduced foreign interest.
- Stock trading sideways near DMA levels, lacking strong momentum.
Company Negative News
- No major negative news reported, but growth concerns persist due to weak PEG ratio.
Company Positive News
- Consistent quarterly profit growth (+10.4%).
- DII stake increased, showing domestic institutional support.
Industry
- Pharmaceutical sector remains resilient with long-term demand drivers.
- Industry P/E of 30.9 reflects optimism in healthcare stocks.
Conclusion
✅ Gland Pharma is financially stable with no debt and fair valuation compared to industry peers. However, moderate profitability and a negative PEG ratio limit its long-term attractiveness. Ideal entry is near ₹1,650–₹1,720. Existing investors should hold with caution for 2–3 years, considering partial profit booking near ₹2,050–₹2,100 resistance levels.